NeuroVive Pharmaceutical and to-BBB have entered into a partnership to develop therapies for stroke and neurodegenerative diseases.
The joint programme will combine to-BBB's proprietary G-Technology, used to enhance drug delivery to the brain, and NeuroVive's cyclosporin-based pharmaceuticals, which are used for the treatment of traumatic brain injuries.
Under the agreement, NeuroVive will fund the initial development up to the clinical proof of concept, after which the two companies will develop and commercialise the product jointly.
Dr Eskil Elmér, CSO of NeuroVive, said that the collaboration with to-BBB opened up the possibility of treating brain disorders beyond traumatic brain injuries.
"There is a tremendous unmet medical need in treating patients with acute neurodegeneration such as stroke, cardiac-arrest-induced brain damage and spinal cord injuries, where one can expect the blood-brain barrier to significantly prevent drug penetration to the central nervous system", Elmér added.
Twitter